Top Page
Botanix Pharmaceuticals Limited
(Sydney:BOT)
Botanix Pharmaceuticals Limited (BOT) vs. iShares MSCI Australia ETF (EWA)
Botanix Pharmaceuticals Limited Business Overview & Revenue Model
Botanix Pharmaceuticals Limited Earnings Call Summary
Botanix Pharmaceuticals Limited Financial Statement Overview
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 21.92M | 5.79M | 601.82K | 914.97K | 2.75M | 6.89M |
| Gross Profit | -25.91M | 2.02M | -6.12M | -3.05M | -7.54M | 315.80K |
| EBITDA | -82.23M | -80.65M | -15.25M | -12.63M | -15.74M | -10.06M |
| Net Income | -88.70M | -86.40M | -13.87M | -9.15M | -13.17M | -3.33M |
Balance Sheet | ||||||
| Total Assets | 98.57M | 129.10M | 112.46M | 24.84M | 14.04M | 21.95M |
| Cash, Cash Equivalents and Short-Term Investments | 31.61M | 64.97M | 79.31M | 10.25M | 7.29M | 21.55M |
| Total Debt | 30.67M | 32.51M | 0.00 | 0.00 | 122.41K | 259.32K |
| Total Liabilities | 44.58M | 47.80M | 3.73M | 1.88M | 5.89M | 1.15M |
| Stockholders Equity | 54.00M | 81.30M | 108.73M | 22.95M | 8.15M | 20.80M |
Cash Flow | ||||||
| Free Cash Flow | -80.86M | -78.87M | -26.13M | -19.13M | -14.11M | -2.98M |
| Operating Cash Flow | -80.66M | -78.58M | -8.13M | -12.07M | -11.18M | -2.97M |
| Investing Cash Flow | -637.53K | -1.05M | -18.00M | -7.05M | -2.92M | -8.28K |
| Financing Cash Flow | 64.77M | 65.36M | 95.10M | 22.03M | -152.41K | -125.50K |
Botanix Pharmaceuticals Limited Technical Analysis
Botanix Pharmaceuticals Limited Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | AU$483.94M | 14.96 | 13.29% | 0.38% | 7.76% | 1.55% | |
53 Neutral | AU$95.38M | -2.00 | -131.13% | ― | 456.50% | -457.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
44 Neutral | AU$195.13M | -5.17 | -83.97% | ― | 1271.12% | 36.87% | |
42 Neutral | AU$738.77M | -4.51 | 132.37% | ― | -80.08% | 59.91% | |
41 Neutral | AU$199.41M | -12.98 | -44.80% | ― | 42.05% | -0.84% | |
40 Underperform | AU$73.69M | -3.40 | -35.86% | ― | ― | -19.21% |
Botanix Pharmaceuticals Limited Corporate Events
Botanix Pharmaceuticals has announced its participation in the annual Euroz Hartleys Institutional Conference, where CEO Dr Howie McKibbon is scheduled to deliver a company presentation. The appearance underscores Botanix’s efforts to raise its profile among institutional investors following FDA approval of Sofdra, positioning the company to highlight its commercial dermatology strategy and growth prospects to key market stakeholders.
The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Insignia Financial Ltd, on behalf of itself and its subsidiaries including IOOF and MLC entities, has notified Botanix Pharmaceuticals that it has ceased to be a substantial shareholder as of 12 March 2026. The change follows a series of on-market trades over recent months, with significant selling of BOT shares ultimately reducing Insignia’s holding below the substantial shareholder threshold, signalling a shift in the company’s institutional investor base that existing shareholders and market participants may monitor for its impact on liquidity and ownership concentration.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals will release 3,111,145 fully paid ordinary shares from voluntary escrow on 20 March 2026, increasing the number of tradable shares on the market. The move may enhance liquidity in Botanix stock and follows the company’s recent progress in commercial dermatology, including its FDA-approved Sofdra treatment for primary axillary hyperhidrosis.
The release of escrowed shares could modestly alter the shareholder base as previously restricted holders gain the ability to trade, though no change in control has been indicated. Investors will be watching how the additional free-float interacts with market demand for Botanix, which is positioning itself around Sofdra as a differentiated therapy in the hyperhidrosis segment.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has updated investors on its proposed issue of securities tied to a securities purchase plan, confirming it has released a prospectus and revised the SPP timetable. The offer under the SPP will now open on 11 March 2026 and close on 13 April 2026, aligning the capital-raising schedule with regulatory and shareholder approval milestones.
A shareholder meeting to approve the issue of securities is set for 1 April 2026, with the company planning to issue the new securities on 20 April 2026, subject to that approval. The revised timetable provides shareholders with clearer visibility on key dates for participation in the SPP and signals continued use of equity markets to support Botanix’s funding needs and strategic initiatives.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has updated investors on its plans for a new issue of securities under a share purchase plan, conducted via a prospectus and structured as a non-pro rata offer. The company is seeking quotation of the new securities on the ASX, in line with its strategy of using equity markets to fund ongoing operations and growth initiatives.
The revised timetable sets the SPP offer period from 11 March to 13 April 2026, with a shareholder meeting on 1 April to approve the issuance. Subject to that approval, the new securities are scheduled to be issued on 20 April 2026, clarifying the capital-raising timeline for existing shareholders and potential participants in the offer.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has opened its security purchase plan as part of a broader capital raising, offering eligible shareholders up to A$30,000 of new shares at A$0.06 each. Participants will also receive one option per new share, exercisable at A$0.06 and expiring on 31 January 2027, with the SPP underwritten to A$5 million and the ability to accept oversubscriptions.
The offer, made under a newly lodged prospectus, is subject to shareholder approval at a general meeting on 1 April 2026 and is scheduled to close on 13 April 2026. The capital injection is intended to strengthen Botanix’s financial position as it advances commercialisation of its dermatology portfolio, following FDA approval of Sofdra for primary axillary hyperhidrosis.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals is launching a security purchase plan that allows eligible shareholders to subscribe for up to A$30,000 of new fully paid ordinary shares at A$0.06 each, with one new option attached to each share. The plan is underwritten to A$5 million by Euroz Hartleys and Canaccord Genuity, with the ability to accept oversubscriptions, reinforcing the company’s effort to secure additional growth capital.
Any shortfall from the shareholder offer up to the underwritten amount may be allocated to the joint lead managers and sub-underwriters on the same terms, alongside separate option offers to placement participants and sub-underwriters. The issuance of all new securities is contingent on shareholder approval of interconditional resolutions at a forthcoming general meeting, meaning investors’ support will directly determine whether the proposed capital-raising structure proceeds.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$1.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has released its 2026 half-year investor presentation dated 3 March 2026, outlining general information for investors and clarifying that the material is not a prospectus or an offer of securities. The document emphasises regulatory and geographic restrictions on distribution, extensive disclaimers on the accuracy and completeness of the information provided, and cautions regarding forward-looking statements about its products and regulatory outcomes.
The presentation reiterates that any investment decisions must be based on investors’ own investigations and professional advice, as Botanix does not provide financial product advice and assumes no liability for reliance on the material. The release, authorised by the company’s board, underscores compliance with Australian securities laws and highlights that its securities are not being offered or sold in the United States under the US Securities Act framework.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has called a general meeting of shareholders for 1 April 2026 in Perth, advising investors that meeting materials will be provided electronically unless hard copies have been specifically requested. The board is urging shareholders to lodge directed proxy forms ahead of the deadline on 30 March to ensure their votes are counted.
The meeting will consider a set of interdependent resolutions tied to a capital raising announced in February 2026, including the second tranche of a placement, a security purchase plan and related option issues. The company warns that if these resolutions fail, it will forfeit access to further funds beyond about A$14.9 million already raised, potentially leaving it without sufficient capital for its planned activities and exposing shareholders to solvency and additional financing risks.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has outlined details of its previously announced capital raising, including a two-tranche placement targeting A$40 million and an underwritten security purchase plan of up to A$5 million, offering eligible shareholders up to A$30,000 in new shares at A$0.06 each with 1:1 attaching options, all subject to shareholder approval at an extraordinary general meeting on 1 April 2026. The ASX has granted Botanix a waiver from Listing Rule 7.3.9 so that eligible shareholders can vote on the issue of securities under the SPP, removing a potential procedural hurdle and enabling broader shareholder participation in approving the equity raising, while still requiring voting exclusions for any underwriters and maintaining compliance with other listing rules.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has issued a correction to its Appendix 4D, clarifying that revenue for the half year ended 31 December 2024 was $345,673 due to a typographical error in the previously disclosed figure. The company stressed that this correction is purely clerical, does not alter its financial statements or results, and leaves all other previously released information unchanged.
For the half year to December 2025, Botanix reported a sharp increase in revenue to $16.5 million, up 4,675% on the prior corresponding period, driven by the commercial progress of its dermatology portfolio. However, the company continued to post a significant loss, with a pre-tax and after-tax loss of about $33.2 million and a decline in net tangible assets per share, underlining ongoing investment and cost pressures as it builds out its market position following Sofdra’s approval.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.05 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals reported a sharp increase in revenue from ordinary activities to $16.5 million for the half year ended 31 December 2025, up from just $34,673 a year earlier, but the business remains loss-making with a pre‑tax and after‑tax loss of $33.2 million, slightly higher than the prior corresponding period. Overall comprehensive loss widened to $33.7 million as other comprehensive income swung negative, while net tangible assets per share fell from 2.71 cents to 1.39 cents and the company again declared no interim or final dividend, underscoring ongoing balance sheet pressure and a continued focus on reinvestment over shareholder payouts.
Basic and diluted earnings per share from continuing operations were a loss of 1.69 cents, marginally improved from a 1.70 cent loss in the prior period, indicating that the substantial revenue growth has yet to translate into profitability. The deterioration in net tangible assets per share and absence of dividends suggest investors face continued near‑term dilution and limited income returns as Botanix prioritises funding operations and advancing its pharmaceutical portfolio.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals, a commercial dermatology company based in Philadelphia and Phoenix, develops and markets innovative skin treatments, led by Sofdra, the first FDA‑approved new chemical entity for primary axillary hyperhidrosis. The drug addresses a major unmet need for patients who have had limited effective options for this socially burdensome condition.
The company has opened registration for an investor webinar on 3 March 2026, where senior executives will present and discuss its Half Year Financial Report. The event signals an effort to enhance transparency and engagement with investors, potentially offering fresh insight into the early commercial performance of Sofdra and Botanix’s broader financial and strategic outlook.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has completed tranche one of a planned A$40 million equity placement, raising approximately A$14.9 million before costs through the issue of nearly 248 million new shares at A$0.06 each to institutional and sophisticated investors. The remaining funds are to be raised subject to shareholder approval at a general meeting expected in early April 2026, and the newly issued shares can trade immediately under applicable Australian securities law exemptions.
The capital raising strengthens Botanix’s balance sheet as it advances its dermatology portfolio following FDA approval of Sofdra for primary axillary hyperhidrosis, positioning the company to capitalise on its first-in-class therapy in a niche but underserved market. The immediate tradeability of the new shares may enhance liquidity for existing and new investors, while shareholder approval for the second tranche remains a key step for the full funding package.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has applied to the ASX for quotation of 247,994,473 new ordinary fully paid shares, scheduled to be issued on 24 February 2026. The securities arise from previously announced transactions, and their listing will significantly expand the company’s quoted share base, with implications for liquidity and ownership dispersion among existing and new investors.
The move underscores Botanix’s continued use of equity markets to fund its activities and strategic initiatives. Increased free float may enhance trading volumes and market visibility, while also potentially diluting existing shareholders depending on the structure and purpose of the earlier transactions that created these securities.
The most recent analyst rating on (AU:BOT) stock is a Sell with a A$0.06 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has opened registration for an investor webinar to be held on 27 January 2026, where senior executives will discuss the company’s Quarterly Activity Report, 4C Quarterly Cash Flow Report and provide an update on its recently approved Sofdra (sofpironium) 12.45% topical gel for primary axillary hyperhidrosis. The event underlines Botanix’s efforts to increase transparency with investors and highlight the commercial progress and strategic significance of Sofdra, which is central to the company’s positioning in the dermatology market.
The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals Ltd has applied for quotation on the ASX of 1,771,429 new fully paid ordinary shares, following the exercise or conversion of existing options or other convertible securities. The additional shares, issued on 20 January 2026, will modestly increase the company’s free float and share capital base, potentially improving liquidity for investors and reflecting ongoing utilisation of equity-linked instruments in its capital structure.
The most recent analyst rating on (AU:BOT) stock is a Hold with a A$0.13 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has cancelled 6,928,586 fully paid ordinary shares following an employee share scheme buy-back, effective 29 December 2025. The reduction in issued capital marginally tightens the company’s share base and may have implications for existing shareholders by modestly improving per-share metrics and signalling active management of its employee equity programs.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has completed an employee share scheme buy-back of 6,928,586 ordinary fully paid shares, as disclosed in its final buy-back notification to the ASX dated 30 December 2025. The transaction, recorded with zero consideration payable, appears to be a technical or administrative cancellation of securities under an employee scheme, modestly tightening the company’s share base and potentially affecting equity allocation among existing shareholders without implying a cash outlay by the company.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has updated the market on its ongoing employee share scheme buy-back, confirming that 6,928,586 ordinary fully paid shares were repurchased on the previous trading day, with no shares bought back before that date. The daily notification underscores the company’s active capital management via buy-backs under its employee equity arrangements, which can influence its share structure and may have implications for existing shareholders’ ownership percentages and the liquidity of BOT shares.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has notified the market of the issue of 8.75 million unquoted options, each exercisable at A$0.125 and expiring on 24 December 2029, under an employee incentive scheme. The award of these unlisted options, which are not intended to be quoted on the ASX, is designed to align staff incentives with shareholder value creation and may modestly increase potential future dilution if exercised.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.
Botanix Pharmaceuticals has applied for quotation on the ASX of 4.6 million new ordinary fully paid shares, following the issue of these securities on 18 December 2025. The additional quotation expands the company’s listed share capital, potentially enhancing liquidity in its stock and providing greater flexibility for capital management and future corporate activities.
The most recent analyst rating on (AU:BOT) stock is a Buy with a A$2.00 price target. To see the full list of analyst forecasts on Botanix Pharmaceuticals Limited stock, see the AU:BOT Stock Forecast page.